Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by CharlesJosef S Smolen
3 March 2021
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et alSofia Ramiro, Rémy L M Mostard, Robert B M Landewé
16 February 2021
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’Maria De Santis, Antonio Voza, Victor Savevski, Salvatore Badalamenti, Maurizio Cecconi, Alberto Mantovani, Carlo Selmi
16 February 2021
Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et alMartin Schäfer, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F Mateus, Laure Gossec, Philip C Robinson, Jinoos Yazdany, Pedro M Machado
1 March 2021
Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’Young Ho Lee
27 January 2021
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et alShintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
15 January 2021
Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?Emine Duran, Levent Kilic, Gamze Durhan, Ahmet Çağkan Inkaya, Gulay Sain Guven, Gul Karakaya, Orhan Macit Ariyurek, Omer Karadag
24 July 2020
Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’Tomoyuki Kawada
27 January 2021
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by LeeShintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
27 January 2021
Response to: ‘Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’’ by KawadaSilvia Piantoni, Laura Andreoli, Enrico Colombo, Monia Mendeni, Maria Laura Ghirardelli, Antonio Brucato, Massimo Imazio, Roberto Furloni, Franco Franceschini, Paolo Airó, Mirko Scarsi
27 January 2021
